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Abstract
Background: Extra-genital Neisseria gonorrhoeae and Chlamydia trachomatis infections are mostly asymptomatic,
and important reservoir sites of infection as they often go undetected and may be more difficult to eradicate with
recommended therapeutic regimens. Commercial nucleic acid amplification tests (NAATs) have not received
regulatory approval for the detection of N. gonorrhoeae and C. trachomatis in extra-genital specimens. The
HOLOGIC® APTIMA Combo2 assay for N. gonorrhoeae and C. trachomatis has performed well in evaluations using
extra-genital specimens.
Methods: We assessed the performance of an in-house real-time duplex PCR assay for the detection of N.
gonorrhoeae and C. trachomatis in urine and extra-genital specimens using the HOLOGIC® APTIMA assays as gold
standard comparators. Urine, oropharyngeal and ano-rectal specimens were collected from each of 200 men-who-
have-sex-with-men (MSM) between December 2011 and July 2012.
Results: For N. gonorrhoeae detection, the in-house PCR assay showed 98.5–100% correlation agreement with the
APTIMA assays, depending on specimen type. Sensitivity for N. gonorrhoeae detection was 82.4% for ano-rectal
specimens, 83.3% for oropharyngeal specimens, and 85.7% for urine; and specificity was 100% with all specimen
types. The positive predictive value (PPV) for N. gonorrhoeae detection was 100% and the negative predictive value
(NPV) varied with sample type, ranging from 98.5–99.5%. For C. trachomatis detection, correlation between the
assays was 100% for all specimen types. The sensitivity, specificity, PPV and NPV of the in-house PCR assay was
100% for C. trachomatis detection, irrespective of specimen type.
Conclusion: The in-house duplex real-time PCR assay showed acceptable performance characteristics in
comparison with the APTIMA® assays for the detection of extra-genital N. gonorrhoeae and C. trachomatis.
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Background
Chlamydia trachomatis and Neisseria gonorrhoeae are
among the most prevalent sexually transmitted patho-
gens worldwide [1, 2]. The majority of chlamydial and
gonococcal infections are asymptomatic and regular
screening is recommended for at-risk sexually active in-
dividuals [3–5]. Simultaneous asymptomatic infection
with both gonorrhoea and chlamydia is not uncommon,
particularly among men-who-have-sex-with-men (MSM)
[6, 7]. Effective screening for sexually transmitted infec-
tion (STI) pathogens is important for the appropriate
management of infected individuals and their partners,
and prevention of further transmission [8].
Published data support the fact that commercial nu-
cleic acid amplification tests (NAATs) are more sensitive
than culture for the diagnosis of N. gonorrhoeae and C.
trachomatis infections across a range of specimen types
and under varying conditions [4, 5, 9]. Even though cul-
ture is still regarded as the ‘gold standard’ for detection
and diagnosis of N. gonorrhoeae from extra-genital sites
[10, 11], multiple studies have shown that it is in fact an
insensitive diagnostic tool for detecting infections at
such sites [7, 12]. In the past, cell culture was performed
for the detection of C. trachomatis in both genital and
extra-genital specimens [12, 13]. These culture methods
are time-consuming, expensive and labour intensive pro-
cedures that require specific and careful specimen hand-
ling and transport conditions for viable organisms to
reach the laboratory [3, 10, 12, 14]. This is not always
feasible, especially where there are long distances be-
tween clinical and diagnostic facilities or in resource
poor settings [3, 10]. The alternative is to use NAATs,
which have been shown to be more sensitive and specific
for the detection of N. gonorrhoeae and C. trachomatis
in urine [3], penile glans [15], ano-rectal [7, 11, 12, 15,
16] and oropharyngeal [7, 11, 12, 17] specimens. NAAT
specificity varies by assay used and by anatomical site
screened [7, 12, 15, 18, 19].
Regulatory approval from the US Food and Drug Ad-
ministration (FDA) has been received for use of the fol-
lowing commercial NAATs for the detection of N.
gonorrhoeae and C. trachomatis in urogenital specimens:
Abbott RealTime m2000 CT/NG (Abbott Molecular Inc.
Des Plaines, IL, USA), Amplicor and Cobas CT/NG test
(Roche Molecular Diagnostics, Branchburg, NJ, USA),
APTIMA (HOLOGIC®, San Diego, CA, USA), BD Pro-
beTec ET and Qx (Becton Dickinson, Sparks, MD, USA)
and Xpert® CT/ NG Assay (Cepheid, Sunnyvale, CA,
USA) [2]. Extra-genital pharyngeal and ano-rectal swab
specimens are not officially approved for use with the
APTIMA Combo 2 assay, even though they have dis-
played acceptable performance characteristics in evalua-
tions [2, 9, 15, 16]. Each laboratory is required to
perform their own validation and verification of data to
support the results obtained from these sample sites ac-
cording to the Clinical Laboratory Improvement
Amendments (CLIA) regulatory requirements [15, 20].
A validated in-house real-time multiplex PCR assay is in
use for the detection of N. gonorrhoeae, C. trachomatis,
Trichomonas vaginalis and Mycoplasma genitalium infec-
tion in endocervical, vaginal, urethral swabs and male
first-pass urine at the Centre for HIV and STIs (CHIVSTI),
National institute for Communicable Diseases (NICD) in
Johannesburg, South Africa (data not presented). However,
this assay has never been evaluated for use with either oro-
pharyngeal or ano-rectal swabs specimens.
For the purpose of this study, the validated in-house
real-time multiplex PCR was modified to a duplex PCR by
incorporating only the primers and probes for the N. gonor-
rhoeae and C. trachomatis targets. We evaluated the per-
formance characteristics of the DNA-based in-house duplex
PCR assay in comparison to the rRNA-based HOLOGIC®
APTIMA assays (APTIMA Combo 2 or APTIMA GC +/−
APTIMA CT) for the detection of N. gonorrhoeae and C.
trachomatis in urine and extra-genital specimens.
Methods
Study population
This study utilised specimens that were collected during
a cross-sectional study of symptomatic and asymptom-
atic STIs among MSM in Cape Town, South Africa [21].
MSM patients attending the Ivan Toms Centre for
Men’s Health were recruited into the original study and
written informed consent obtained from all participants.
This is a state-sector clinic that delivers locally appropri-
ate sexual health care such as STI and HIV screening
and treatment and pre-exposure prophylaxis (PrEP)
provision to gay, bisexual and other MSM, as well as the
transgender community of the Western Cape, regardless
of socio-economic status. A total of 200 consecutive
MSM, 18 years of age or above, and reporting sexual ac-
tivity with another man within the last 12 months, were
enrolled from December 2011 through to July 2012. Eth-
ics approval (Protocol number: HSREC 419/2011) was
obtained from the Human Sciences Research Ethics
Committee at the University of Cape Town.
Specimen collection and transport
Ano-rectal and oropharyngeal swabs (clinician col-
lected) and a self-collected first-pass urine (20 ml) spe-
cimen were obtained from each of the 200 participants.
The oropharyngeal and ano-rectal swab specimens were
collected using the APTIMA Unisex Swab Collection
kit (HOLOGIC®, San Diego, CA, USA). A two millilitre
aliquot of urine from each patient was transferred to an
APTIMA Urine Collection kit for Male and Female
specimens tube (HOLOGIC®) within 24 h after collec-
tion as per manufacturer’s instructions. All specimens
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were stored at 2–8 °C and transported to the laboratory




The APTIMA Combo 2 assay is a second generation
NAAT probe test that uses target capture, transcription
mediated amplification and dual kinetic assay technology
to differentiate between the 23S rRNA of N. gonorrhoeae
and 16S rRNA of C. trachomatis in clinical specimens.
Assay test results, based on chemiluminescent detection,
are automatically interpreted by the APTIMA assay soft-
ware. Testing of the three specimen types (urine, oro-
pharyngeal and ano-rectal swabs) was performed,
according to the manufacturer’s instructions, using a
400 μl volume of each specimen. Indeterminate results
on the APTIMA Combo 2 assay, or discordant results
between the APTIMA Combo 2 and in-house real-time
PCR assays, were resolved by using a third “tie-breaker”
assay, either APTIMA GC or APTIMA CT assay, which
uses different 16S rRNA primer targets from the
APTIMA Combo 2 assay. The kits contain standardised
positive controls for each target.
In-house real-time duplex PCR assay for the detection of N.
gonorrhoeae and C. trachomatis infection
Genomic DNA was extracted from 200 μl urine and
swab specimens stored in HOLOGIC® APTIMA collec-
tion tubes using the MagNA Pure LC DNA isolation kit
I (Roche Molecular Diagnostics, Mannheim, Germany)
on the automated MagnaPure LC2.0 platform (Roche).
The extracted DNA was subsequently used in down-
stream PCR assay applications.
The in-house real-time duplex PCR assay primers and
probes target the N. gonorrhoeae cytosine-specific DNA
methyl transferase gene and the cryptic plasmid of C.
trachomatis. For N. gonorrhoeae the forward primer se-
quence is 5′-GGA TAC GAC GTA ACC TTG ACT
ATG G-3′, the reverse primer sequence is 5’-CCG ATG
TAG AAG ACC CTT TTG C-3′ and the TaqMan probe
sequence is 5′-[AMINO C6 + ROX] CA ACG CCA
AAG ACT ACG GTG TAG CAC AG [BHQ2a]-3′. For
C. trachomatis the forward primer sequence is 5′-GGA
TTG ACT CCG ACA ACG TAT TC-3′, the reverse pri-
mer sequence is 5’-ATC ATT GCC ATT AGA AAG
GGC ATT-3′ and the TaqMan probe sequence is
5′-[6-FAM]TT ACG TGT AGG CGG TTT AGA AAG
CGG [BHQ1a]-3′. The 25 μl PCR master mix consisted
of 5 U AmpliTaq Gold with GeneAmp 1X PCR buffer,
25 mM MgCl2 (Applied Biosystems, New Jersey, USA)
and 400 μM dUTP mix (Bioline GmbH, Berlin,
Germany). Target-specific, custom designed C. tracho-
matis primers (300 nM) and probe (200 nM) and N.
gonorrhoeae primers and probe (200 nM each) were
added to the master mix. A total of 25 μl extracted DNA
was added to the master mix and the real-time PCR
assay was performed on the RotorGene™ 3000/6000
(QIAGEN®) platforms as described previously [22]. DNA
extracts from the N. gonorrhoeae ATCC strain 700,825
and C. trachomatis ATCC strain VR-885 were used as
positive controls.
Data analysis
The performance characteristics of the in-house
real-time duplex PCR assay i.e. sensitivity, specificity,
PPV and NPV for detection of N. gonorrhoeae and C.
trachomatis in extra-genital and urine specimens were
calculated by comparing results of in-house real-time
duplex PCR and APTIMA assays. The APTIMA
Combo 2 assay was considered the gold standard
diagnostic method, but the APTIMA GC and/or
APTIMA CT assays were used for the resolution of
equivocal or discordant results with the APTIMA
Combo 2 assay, in order to get a definitive end result.
The percentage correlation or agreement between the
assays was also calculated.
Results
Urine specimens: Of the 200 urine specimens, six (3.0%)
tested positive for N. gonorrhoeae and seven (3.5%) for
C. trachomatis with both NAAT assays. There were no
mixed infections detected in the urine specimens. One
(0.5%) specimen tested positive for N. gonorrhoeae on
the APTIMA Combo 2 assay (and was confirmed posi-
tive by APTIMA GC assay), but tested negative with the
in-house duplex PCR assay.
Five (2.5%) specimens with equivocal results for N.
gonorrhoeae on APTIMA Combo 2 assay were tested
using the APTIMA GC assay and negative results, which
correlated with the in-house real-time duplex PCR assay
results, were obtained.
Oropharyngeal specimens: Of the 200 specimens,
194 specimens contained sufficient DNA extract for
use in further testing. A total of 10/194 (5.2%) oro-
pharyngeal specimens tested positive for N. gonor-
rhoeae with both NAATs. Discordant results for N.
gonorrhoeae were observed for two specimens (1.0%)
that tested negative with the in-house duplex PCR
assay, but positive with APTIMA Combo 2 as well as
the APTIMA GC assays. Five (2.6%) specimens with
equivocal results for N. gonorrhoeae on APTIMA
Combo 2 assay were tested using the APTIMA GC
assay. The negative results obtained with the
APTIMA GC assay for all five specimens correlated
with the in-house real-time duplex PCR assay results.
C. trachomatis was not detected in any oropharyngeal
specimens when tested with either NAAT platform.
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Ano-rectal specimens: Of the original 200 specimens,
199 were available for further testing. N. gonorrhoeae
and C. trachomatis co-infections were detected in seven
(3.5%) specimens with both assays. For N. gonorrhoeae,
single infections were detected in 7/199 (3.5%) of speci-
mens with both NAATs. Another three (1.5%) specimens
tested positive for N. gonorrhoeae with the APTIMA
Combo2 and APTIMA GC assays, but negative with the
in-house duplex PCR assay. Six (3%) specimens resulted
in APTIMA Combo 2 equivocal results for N. gonor-
rhoeae and were repeat tested with the APTIMA GC
assay. All six specimens tested negative with the
APTIMA GC assay, and these results were in agreement
with those obtained with the in-house real-time duplex
PCR assay. For C. trachomatis, single infections were de-
tected in 8/199 (4.0%) specimens by both NAATs.
Performance characteristics of the in-house real-time
duplex PCR assay compared to the gold standard APTIMA
assays
The performance characteristics (sensitivity, specificity,
PPV and NPV) of the in-house real-time duplex PCR
assay was evaluated in comparison to the gold standard
APTIMA Combo2 assay, (and the APTIMA CT and/or
APTIMA GC assays if an equivocal result was obtained
with the APTIMA Combo2), for the detection of N.
gonorrhoeae and C. trachomatis in the different specimen
types tested (Tables 1 and 2). The percentage correlation
between the two test methods for the detection of N.
gonorrhoeae was 98.5% with ano-rectal specimens, 99%
with oropharyngeal specimens and 99.5% with urine. For
C. trachomatis the percentage correlation between the as-
says was 100% across all the specimen types tested.
Discussion
We compared the performance characteristics of an
in-house real-time duplex PCR assay with that of com-
mercial HOLOGIC® APTIMA assays for the detection of
N. gonorrhoeae and C. trachomatis in urine and
extra-genital specimens. The percentage correlation be-
tween the assays for the detection of N. gonorrhoeae
ranged from 98.5–99.5% depending on specimen type
tested, but for C. trachomatis, it was 100% for all the
specimen types tested.
Even though the analytical sensitivity of the APTIMA
system is unknown, it may be as low as 1 inclusion form-
ing unit in the case of C. trachomatis and less than 50 cells
per assay for N. gonorrhoeae, according to the manufac-
turer’s package insert. The detection limit for the in-house
real-time duplex PCR assay in our laboratory is also un-
known, but an evaluation conducted at the US Centres for
Disease Control and Prevention (CDC) showed similar
analytical sensitivity of 1–10 genomic copies of N. gonor-
rhoeae and 0.1 inclusion-forming unit of C. trachomatis
(personal communication, Dr. Chen, CDC).
There may be several reasons for the discordant results
between the APTIMA and in-house duplex PCR assays.
Nucleic acid extraction was done on 200 μl of the
specimen-containing transport medium tube for the
in-house duplex PCR assay, whereas the APTIMA assay
systems require double that volume, i.e. a minimum test-
ing volume of 400 μl. Because of the target mediated amp-
lification (TMA) step in the APTIMA Combo 2 assay, it
can detect even a very low target copy number and in-
crease the target sites exponentially and faster than a con-
ventional PCR assay approach, resulting in higher
amplification levels, and therefore better detection. The
sensitivity is increased by the target capture of rRNA
genes that are present in higher copy numbers in the bac-
terial cell than the target analytes of the in-house duplex
PCR assay. Ideally, first void specimens should be used to
increase the sensitivity of NAAT, but this was not possible
for this evaluation. These factors could explain why two
oropharyngeal, three ano-rectal specimens, and one urine
specimen tested positive for N. gonorrhoeae with the
APTIMA Combo 2 assay, but negative on the in-house
Table 1 Performance characteristics of the in-house real-time duplex PCR assay for the detection of N. gonorrhoeae
Specimen type COMPARATOR – HOLOGIC® APTIMA assays
Oropharyngeal swab Ano-rectal swab Urine
TEST: PCRa Positive Negative Total Positive Negative Total Positive Negative Total
Positive 10 0 10 14 0 14 6 0 6
Negative 2 182 184 3 182 185 1 193 194
Total 12 182 194 17 182 199 7 193 200
Sensitivity 83% 82.4% 85.7%
Specificity 100% 100% 100%
PPV 100% 100% 100%
NPV 98.9% 98.4% 99.5%
% Agreement 99% 98.5% 99.5%
aPCR = in-house duplex real time PCR assay
Venter et al. BMC Infectious Diseases            (2019) 19:6 Page 4 of 7
duplex PCR assay platform. Due to the target-specific cap-
ture step during the TMA part of the APTIMA assay sys-
tem most, if not all, inhibitors are removed from the
system and the pure target extracted before amplification
ensues. This is not necessarily the case for the
non-target-specific magnetic-based nucleic acid extraction
method, where all nucleic acid material from a specimen
is extracted. TMA has been shown to be more sensitive
than other NAATS in previous evaluations [5, 12, 15]. An-
other explanation for discrepancies could be that at the
time of PCR testing, the duplex PCR assay did not include
a target for an internal human DNA control in order to
validate the quality of the extracted DNA. It is possible
that DNA extraction and subsequent downstream amplifi-
cation methods failed for these specimens. The issue, of
including an internal human DNA control target into the
in-house real-time duplex PCR assay, has since been ad-
dressed and the assay has been re-validated.
Use of the in-house real-time duplex PCR assay has
certain advantages over the APTIMA Combo 2. The
cost of the commercial APTIMA assay, inclusive of ma-
terials and reagents, is more than twice that of our
in-house PCR assay. The duplex PCR assay can also be
modified to a multiplex PCR format to additionally de-
tect other sexually transmitted pathogens associated
with urogenital discharge, such as T. vaginalis and M.
genitalium. A human-DNA internal control target pro-
vides assurance that nucleic acid extracted is of sufficient
quality for downstream applications. Disadvantages of
the in-house real-time duplex PCR assay include the re-
quirement for more hands-on time and training and that
a maximum of only 36 specimens, inclusive of quality
controls, can be tested in a single run lasting two hours.
With the fully-automated APTIMA system significantly
less hands-on preparation time is required for sample
processing and in-process interaction. It is a random ac-
cess system and the first five results will be available
within three and a half hours. The results of a full run of
100 specimens, inclusive of quality controls, will be
available within five hours.
There are concerns regarding the specificity of NAATs
when testing samples from sites colonised by other com-
mensal Neisseria species [23]. These species are genetic-
ally closely related, and may result in false positive N.
gonorrhoeae results [9, 14, 23]. The same has not been
observed with the APTIMA Combo 2 or the APTIMA
GC assays [9, 17, 19]. Studies have revealed sensitivities
of 100% and specificities of 99.2–99.5% for C. trachoma-
tis detection in oropharyngeal swabs with APTIMA as-
says, compared to the BD ProbeTec ET system, which is
based on strand displacement DNA amplification tech-
nology. Similarly, diagnostic sensitivity for C. trachoma-
tis detection in ano-rectal swabs was reported to be
100% and specificity ranged from 98.7 to 100%. For N.
gonorrhoeae detection in oropharyngeal swabs and rectal
swabs, sensitivity was reported to be 95 and 100%, re-
spectively; and specificities ranged from 99.6–100% and
99.5–100%, respectively [9, 12]. Therefore, APTIMA as-
says were deemed appropriate for use as the gold stand-
ard comparators in our assay evaluation study.
Individuals at risk of contracting STIs include
key-populations such as MSM, adolescents, women ≤24
years of age and pregnant women attending antenatal clinics,
that have documented high prevalence of N. gonorrhoeae
and C. trachomatis infections [2, 4, 5, 21, 24]. In MSM, STIs
occur at both urethral and non-urethral sites, yet screening
of non-urethral or extra-genital sites such as the ano-rectum
and oropharynx remains uncommon [7, 8, 11, 16, 25]. Most
extra-genital infections are asymptomatic [10, 26, 27] and
thus are not diagnosed using the syndromic management ap-
proach, which relies on the presence of symptoms and/or
signs as the entry point to appropriate management algo-
rithms. The most common site of asymptomatic gonococcal
infection in MSM is the oropharynx [21, 25, 26], indicating
that this could be an important reservoir for infection at
genital sites [25]. Having the ability to screen for gonorrhoea
Table 2 Performance characteristics of the in-house real-time duplex PCR assay for the detection of C. trachomatis
Specimen type COMPARATOR – HOLOGIC® APTIMA assays
Oropharyngeal swab Ano-rectal swab Urine
TEST: PCR* Positive Negative Total Positive Negative Total Positive Negative Total
Positive 0 0 0 15 0 15 7 0 7
Negative 0 194 194 0 184 184 0 193 193
Total 0 194 194 15 184 199 7 193 200
Sensitivity N/A** 100% 100%
Specificity 100% 100% 100%
PPV N/A** 100% 100%
NPV 100% 100% 100%
% Agreement 100% 100% 100%
*PCR = in-house duplex real-time PCR assay
**N/A = Not applicable, since no C. trachomatis were detected, these values could not be calculated
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and chlamydia at extra-genital sites with inexpensive labora-
tory or point-of-care tests would revolutionize STI screening
in key populations, such as MSM and sex workers, in
resource-poor settings.
In addition to MSM, some of whom reside within
high-risk core groups or who may act as a bridge for bacter-
ial STI transmission to the wider community [28], there is a
large heterosexual population at risk of infection at
extra-genital sites [16, 29]. Treatment failures in patients
with N. gonorrhoeae infection due to antimicrobial resist-
ance or reduced antimicrobial susceptibility are well docu-
mented [23, 30–32]. N. gonorrhoeae infection of the
oropharynx is more difficult to eradicate than infections at
urogenital sites and may therefore persist despite the ad-
ministration of recommended treatment. The oropharynx is
an anatomical site that facilitates the acquisition of anti-
microbial resistance determinants through genetic exchange
between oral commensal and pathogenic bacterial patho-
gens [23, 30, 32]. Additionally, extended-spectrum cephalo-
sporins such as cefixime and ceftriaxone, recommended in
current treatment regimens, may not reach adequate and
consistent concentration levels in oropharyngeal tissue [30].
This can lead to selection and spread of gonococci with de-
creased susceptibility to antimicrobials over time, resulting
in treatment failure [33]. It is therefore important to test
extra-genital specimens for N. gonorrhoeae and C. tracho-
matis infection from at-risk individuals, using a sensitive
and specific assay [11, 27, 34].
Conclusion
Our study demonstrated that the in-house real-time du-
plex PCR assay showed acceptable performance character-
istics in comparison to the HOLOGIC® APTIMA assays
for the detection of N. gonorrhoeae and C. trachomatis
from urine, oropharyngeal and rectal specimens. It would
be a relatively inexpensive screening test for these genital
and extra-genital infections.
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